Tumori最新文献

{"title":"Breast implant associated anaplastic large cell lymphoma: Evidence for an efficient diagnostic workup.","authors":"Laura Vittoria,&nbsp;Laura Sala,&nbsp;Valeria Summo,&nbsp;Iolanda Capone,&nbsp;Elena Conca,&nbsp;Martina Toma,&nbsp;Joseph Ottolenghi,&nbsp;Francesca Testa,&nbsp;Umberto Cortinovis,&nbsp;Biagio Paolini,&nbsp;Antonello Cabras,&nbsp;Antonella Aiello,&nbsp;Fabio Bozzi","doi":"10.1177/03008916231157837","DOIUrl":"10.1177/03008916231157837","url":null,"abstract":"<p><strong>Introduction: </strong>During the last few years it has been shown that an anaplastic T cell lymphoma can develop as a rare and late sequelae of implant-based breast reconstruction. This malignancy was recognized in the 2017 by WHO and named breast implant associated anaplastic large T cell lymphoma (BIA-ALCL). BIA-ALCL usually presents as abundant effusion around the implant, thus, in addition to cytology smears, its diagnosis also requires immunohistochemistry, T cells clonality and cytometry. Due to the increasing attention of clinicians, it is likely that the number of the BIA-ALCL suspected cases will grow in the future, implying the necessity of a reliable and cost-effective diagnostic procedure.</p><p><strong>Methods: </strong>To achieve this goal, we retrospectively analyzed the results of laboratory investigations performed at our Institute (Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy) on 44 effusions obtained from 31 women suspected for BIA-ALCL.</p><p><strong>Results: </strong>Through cytology, eight out of 44 effusions showed the presence of BIA-ALCL cells. Lymphoma cells were than confirmed in seven samples by immunohistochemistry and/or T cell clonality and/or cytometry. Overall, cytology showed 100% sensitivity, 97% specificity and positive and negative predictive values of 87.5% and 100% respectively. Further analyses were particularly useful in effusions showing small percentages of BIA-ALCL cells. Moreover, an extended cytometric profile that can be applied when fast confirmation of the cytologic result is required was also identified.</p><p><strong>Conclusions: </strong>Our results evidenced a central role of cytopathology in the management of BIA-ALCL suspected effusions and suggested that further laboratory investigations might be applied only in cases showing atypical/activated lymphoid cells through cytology.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"458-465"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/78/10.1177_03008916231157837.PMC10540484.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9202353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute myeloid leukemia: Incidence, transplantation and survival through Italian administrative healthcare data.","authors":"Silvia Calabria,&nbsp;Giulia Ronconi,&nbsp;Letizia Dondi,&nbsp;Carlo Piccinni,&nbsp;Antonella Pedrini,&nbsp;Immacolata Esposito,&nbsp;Alice Addesi,&nbsp;Giuseppe Rossi,&nbsp;Felicetto Ferrara,&nbsp;Adriano Venditti,&nbsp;Nello Martini","doi":"10.1177/03008916231153698","DOIUrl":"10.1177/03008916231153698","url":null,"abstract":"<p><strong>Objective: </strong>To identify newly diagnosed patients with acute myeloid leukemia in 2017 treated with intensive chemotherapy or unfit for intensive chemotherapy, and to assess their probability of receiving allogeneic stem cell transplantation and survival, from the Italian National Health Service perspective.</p><p><strong>Patients and methods: </strong>From the Ricerca e Salute database, adults with an in-hospital diagnosis of acute myeloid leukemia (International Classification of Disease-9th version-Clinical Modification code 205.0x) in 2017 (index date), without any identifying acute myeloid leukemia criteria within the preceding year, were selected. Among them, subjects treated with intensive chemotherapy (chemotherapy during an overnight hospitalization) within one year after index date were identified. The remaining were considered unfit for intensive chemotherapy. Gender, age and comorbidities were described. Within the follow-up period, probabilities of in-hospital allogeneic stem cell transplantation and overall survival were assessed through Kaplan Meier analyses.</p><p><strong>Results: </strong>From 4,840,063 beneficiaries of the Italian National Health Service, 368 newly acute myeloid leukemia diagnosed adults (9.0 *100,000) were selected. Males comprised 57%. Mean age was 68±15. There were 197 patients treated with intensive chemotherapy. The remaining 171 unfit for intensive chemotherapy were older (72±14) and with more comorbidities (e.g. hypertension, chronic lung diseases and chronic kidney disease). Only patients treated with intensive chemotherapy underwent an allogeneic stem cell transplantation (41; 33%) during the one year after the index date. Within the first and second follow-up year, respectively: 41.1% and 26.9% of subjects treated with intensive chemotherapy (144) survived (median survival time: 7.8 months); 25.7% and 18.7% of those unfit for intensive chemotherapy (139) survived (1.2 months). Difference was significant (p<0.0001). Within one and two years after transplantation (41 patients), 73.5% and 67.3% of subjects survived, respectively.</p><p><strong>Conclusion: </strong>This study, by showing the incidence of acute myeloid leukemia in Italy in 2017, the proportion of patients treated with intensive chemotherapy from the new diagnosis, the use of allogeneic stem cell transplantation and two-year survival, integrated evidence on large and unselected populations and may help to improve treatment strategies of older acute myeloid leukemia patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"496-503"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9435191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral vinorelbine in young patients with desmoid-type fibromatosis.","authors":"Laure Kornreich,&nbsp;Daniel Orbach,&nbsp;Nayla Nicolas,&nbsp;Hervé J Brisse,&nbsp;Pablo Berlanga,&nbsp;Anne-Sophie Defachelles,&nbsp;Ludovic Mansuy,&nbsp;Cécile Verite,&nbsp;Laure Saumet,&nbsp;Marie Karanian,&nbsp;Nadège Corradini","doi":"10.1177/03008916231169806","DOIUrl":"10.1177/03008916231169806","url":null,"abstract":"<p><strong>Background: </strong>Desmoid-type fibromatosis are rare intermediate tumors in children and adolescents. Owing to local aggressiveness and relapse, systemic treatment for symptomatic advanced or progressive forms is recommended. Following promising results in adult patients, oral vinorelbine is investigated in young patients.</p><p><strong>Methods: </strong>A retrospective review of young patients (<25 years old) with advanced or progressive desmoid type fibromatosis treated with oral vinorelbine in eight large centers of the Société Française des Cancers de l'Enfant was performed. In addition to tumor assessment according to RECIST 1.1, pre-treatment and during-treatment imagery were reviewed centrally to assess tumor volume and estimate fibrosis score through the change in percentage in hypoT2 signal intensity.</p><p><strong>Results: </strong>From 2005 to 2020, 24 patients (median age 13.9 years [range, 1.0-23.0]) received oral vinorelbine. Median number of prior systemic lines of treatment was 1 (range, 0-2), mainly based on intravenous low dose methotrexate and vinblastine. Before vinorelbine initiation, all patients had a progressive disease: radiological for 19, radiological and clinical (pain) for three and only clinical for two. Oral vinorelbine was delivered for a median duration of 12 months (range, 1-42). The toxicity profile was favorable, with no grade 3-4 event. Overall response estimated on 23 evaluable patients according to RECIST 1.1 criteria was three partial responses (13%), 18 stabilization (78%) and two progressive disease (9%). Overall progression-free survival was 89.3% (95% confidential intervals 75.2-100) at 24 months. Four stable tumors according to standard RECIST criteria displayed a partial response with > 65% tumor volume reduction. Among 21 informative patients, the estimated fibrosis score decreased for 15 patients, was stable for four patients and increased for two patients.</p><p><strong>Conclusion: </strong>Oral vinorelbine seems to be effective to control advanced or progressive desmoid type fibromatosis in young patients, with a well-tolerated profile. These results support testing this drug as first-line alone or in combination to improve response rate while preserving quality of life.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"511-518"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9726802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.","authors":"Andrea Milani,&nbsp;Valentina Tuninetti,&nbsp;Sandro Pignata,&nbsp;Domenica Lorusso,&nbsp;Daniele Castaldo,&nbsp;Ugo De Giorgi,&nbsp;Antonella Savarese,&nbsp;Nicoletta Biglia,&nbsp;Giuseppa Scandurra,&nbsp;Giorgia Mangili,&nbsp;Massimo Di Maio,&nbsp;Margherita Turinetto,&nbsp;Marco Bellero,&nbsp;Serafina Mammoliti,&nbsp;Silvia Testa,&nbsp;Giulia Scotto,&nbsp;Andrea Purro,&nbsp;Grazia Artioli,&nbsp;Giorgio Valabrega","doi":"10.1177/03008916221146820","DOIUrl":"10.1177/03008916221146820","url":null,"abstract":"<p><strong>Introduction: </strong>Low molecular weight heparin (LMWH) has been the backbone of the treatment of cancer associated thrombosis (CAT). Direct-acting oral anticoagulants (DOACs) have shown efficacy and safety not inferior to LMWH and guidelines included DOACs as an option for CAT treatment. Nevertheless, DOACs are still poorly prescribed in patients with cancer. The aim of this survey was to better understand prescription patterns of anticoagulants, in particular of DOACs, especially in gynecological cancers (GCs).</p><p><strong>Methods: </strong>Our survey was made up of 21 questions, the last four questions addressed to medical doctors (MDs) involved in GCs. An invitation to complete the survey was sent by e-mail to 691 MITO (Multicentre Italian Trials in Ovarian cancer and gynaecologic malignancies) and 2093 AIOM (Associazione Italiana di Oncologia Medica) members.</p><p><strong>Results: </strong>Overall, 113 MDs completed the questionnaire, 69 involved in GCs. Most respondents (46, 41%) were aged 30-40 years old, worked in public hospitals (59, 52.2%), were medical oncologists (86, 76.1%). LMWH was the preferred choice for the treatment of CAT (104, 92%). However, 89 respondents (78.8%) prescribed or asked to prescribe a DOAC for CAT. The major concern about DOACs was the difficulty in verifying the therapeutic effect and the absence of antidotes in case of bleeding (37.9%). In patients with GCs, DOACs were used with niraparib, olaparib, rucaparib and immune checkpoint inhibitors (ICIs) in less than 10 patients by 23%, 20%, 9% and 10.2% of respondents, respectively.</p><p><strong>Conclusion: </strong>The responders are aware of the Direct-acting oral anticoagulants option and would like to use them.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"490-495"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10485022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term outcome of complex surgical resection and reconstruction for rare thoracic cancers.","authors":"Ugo Pastorino,&nbsp;Giovanni Leuzzi,&nbsp;Federica Sabia,&nbsp;Paolo Girotti,&nbsp;Leonardo Duranti,&nbsp;Stefano Radaelli,&nbsp;Marco Fiore,&nbsp;Silvia Stacchiotti,&nbsp;Giannatempo Patrizia,&nbsp;Roberto Salvioni,&nbsp;Alessandro Gronchi","doi":"10.1177/03008916231154763","DOIUrl":"10.1177/03008916231154763","url":null,"abstract":"<p><strong>Background: </strong>Complex surgical resection and reconstruction for rare thoracic cancers (RTCs) represent a major challenge, given their very low frequency, extreme variability of presentation, multi-modality treatment options and inadequate outcome prediction. We analysed the experience of a tertiary referral centre on a consecutive series of patients with thoracic germ cell tumours, thymomas and sarcomas, with the aim of reporting the long-term outcome by cancer type and complexity of surgical procedures.</p><p><strong>Methods: </strong>From Jan 2003 to Dec 2018, 768 surgical procedures were performed with curative intent on 644 RTC patients. Study endpoints were: post-operative hospital stay (Pod), 30-day and 90-day mortality, 5-year and 10-year overall survival (OS). Median follow-up of alive patients was 7.2 years.</p><p><strong>Results: </strong>Median Pod was 7 days, with a 1.2% 30-day and 2.9% 90-day mortality. OS was 90.8% at one year, 74.2% at five years and 62.8% at 10 years. Ten-year OS was 73.0% in low, 65.3% in intermediate, and 55.6% in high complexity score (Log-rank tests p<0.0001); 66.6% in patients with one or two reconstructions and 46.4% in patients with three or more reconstructions (p<0.0001); 46.0% with vascular and 50.0% with chest wall reconstruction; 71.8% in germ cell tumours, 64.6% in thymoma and 51.3% in sarcoma (p<0.0001).</p><p><strong>Conclusion: </strong>Complex surgical resection and reconstruction was associated with acceptable 90-day mortality and good 10-year survival in all RTC types. A predictive score based on surgical complexity and cancer type can help the clinical decision making.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"450-457"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/37/10.1177_03008916231154763.PMC10540492.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9208218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating secondary malignant neoplasms: A burden of childhood cancer survivors.","authors":"Marta G Podda,&nbsp;Cristina Meazza,&nbsp;Giovanna Gattuso,&nbsp;Giovanna Sironi,&nbsp;Olga Nigro,&nbsp;Luca Bergamaschi,&nbsp;Veronica Biassoni,&nbsp;Michela Casanova,&nbsp;Stefano Chiaravalli,&nbsp;Andrea Ferrari,&nbsp;Roberto Luksch,&nbsp;Nadia Puma,&nbsp;Elisabetta Schiavello,&nbsp;Filippo Spreafico,&nbsp;Paolo Grampa,&nbsp;Siranoush Manoukian,&nbsp;Sabina Vennarini,&nbsp;Paola Collini,&nbsp;Primo A Daolio,&nbsp;Massimiliano Gennaro,&nbsp;Marco Guzzo,&nbsp;Carlo Morosi,&nbsp;Davide Biasoni,&nbsp;Maura Massimino,&nbsp;Monica Terenziani","doi":"10.1177/03008916231160824","DOIUrl":"10.1177/03008916231160824","url":null,"abstract":"<p><p>Each year approximately 35,000 children and adolescents are diagnosed with cancer in Europe. Five-year survival rates have improved and now reach 80% in most European countries, thanks to a combination of chemotherapy, radiotherapy, and surgery. To date, there are more than 44,000 Italians still living several years after being diagnosed with cancer in developmental age. The risk of premature morbidity and mortality for cancer survivors is well known and documented. Approximately 60% of survivors of cancer in childhood and adolescence have at least one chronic health condition in later life, and more than one in four develop severe or life-threatening disorders. Among the various long-term iatrogenic sequelae of cancer treatments, the most worrisome are second malignant neoplasms. We reported on our mono-institutional experiences of screening and treating secondary breast cancer, secondary thyroid cancer and secondary osteosarcoma. Recommendations on the surveillance needed for cancer survivors because of the risk of late effects of their disease or its treatment suggest that discussing the potential problems early on can be crucial to a patient's future health. These considerations and our consolidated experience strengthen our conviction that survivors of cancer in childhood and adolescence who develop second malignant neoplasms should be treated at highly-specialized centers. Multidisciplinary care requires close communications and high levels of up-to-date professional expertise. This challenging area of health care is also changing rapidly because cancer survivorship is a work in progress, but we cannot wait for definitive conclusions on many aspects because this will take decades, especially for pediatric patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"436-441"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/0b/10.1177_03008916231160824.PMC10540476.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9523243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice.","authors":"Raffaella D'Onofrio,&nbsp;Francesco Caputo,&nbsp;Francesco Prampolini,&nbsp;Andrea Spallanzani,&nbsp;Fabio Gelsomino,&nbsp;Stefania Bettelli,&nbsp;Samantha Manfredini,&nbsp;Luca Reggiani Bonetti,&nbsp;Pietro Carotenuto,&nbsp;Alessandro Bocconi,&nbsp;Massimo Dominici,&nbsp;Gabriele Luppi,&nbsp;Massimiliano Salati","doi":"10.1177/03008916221122554","DOIUrl":"https://doi.org/10.1177/03008916221122554","url":null,"abstract":"<p><strong>Aim: </strong>To apply extended ctDNA-based RAS genotyping to clinical criteria for improving the selection of patients eligible for anti-EGFR-based rechallenge in a real-world setting.</p><p><strong>Methods: </strong>ctDNA testing was prospectively applied to RASwt mCRC progressed after a first-line anti-EGFR-containing regimen and at least one other line. The primary endpoint was the objective response rate.</p><p><strong>Results: </strong>Among ten enrolled patients, the anti-EGFR rechallenge resulted in an objective response rate and disease control rate of 70% and 90%. The median progression-free survival was 11.3 months and overall survival was not reached. Compared with a historical cohort retreated with anti-EGFR agents based on clinical criteria, the ctDNA-driven approach resulted in a higher chance of achieving an objective response and longer survival.</p><p><strong>Conclusions: </strong>Blood-based RASwt status may enrich metastatic colorectal cancer more likely to benefit from anti-EGFR-based rechallenge. RAS genotyping in ctDNA represents a feasible, fast, and cost-effective tool to be implemented in the clinic for advancing precision medicine.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"387-393"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9843180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide.","authors":"Maria La Vecchia,&nbsp;Ivan Fazio,&nbsp;Nicolò Borsellino,&nbsp;Daniele Galanti,&nbsp;Antonio Lo Casto","doi":"10.1177/03008916221132592","DOIUrl":"https://doi.org/10.1177/03008916221132592","url":null,"abstract":"<p><strong>Introduction: </strong>This monocentric, single-arm, retrospective study investigated the role of stereotactic body radiotherapy in patients with metastatic castration resistant prostate cancer who experienced oligoprogression during androgen receptor targeted agents.</p><p><strong>Methods: </strong>We retrospectively enrolled metastatic castration resistant prostate cancer patients treated with androgen receptor targeted agents between December 2016 and January 2022. All patients experienced an oligoprogression (defined as the appearance and/or the progression of ⩽5 bone or nodal or soft tissue metastases) during treatment with androgen receptor targeted agents and received stereotactic body radiotherapy upon oligoprogressive sites, preserving the androgen receptor targeted agents. Further stereotactic body radiotherapy upon new metastatic sites was permitted. Patients showing visceral metastases or receiving palliative radiotherapy were excluded. Progressive disease at >5 metastatic sites or the appearance of visceral metastases led to a change of the systemic treatment. Primary endpoints were 36-month survival rate and 36-month rate of patients receiving treatment with androgen receptor targeted agents. Secondary endpoints were local disease control, biochemical response and safety.</p><p><strong>Results: </strong>We analyzed data from 30 patients. The 36-month survival rate was 90% (27 patients); 36-month rate of patients who were still on treatment with androgen receptor targeted agents was 50%. 20 of 30 patients had performed imaging control after a single course of stereotactic body radiotherapy: overall response rate was 50%, while clinical benefit was 93%. No ⩾G2 adverse events related to stereotactic body radiotherapy were recorded.</p><p><strong>Conclusions: </strong>Stereotactic body radiotherapy in oligoprogressive metastatic sites during androgen receptor targeted agent treatment resulted in a feasible and effective treatment to delay the start of next-line systemic treatment and prolong overall survival in metastatic castration resistant prostate cancer. Longer follow-up and further prospective studies are necessary to confirm our preliminary results.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"413-417"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9840193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients.","authors":"Sebastiano Buti,&nbsp;Francesca Trentini,&nbsp;Pierangela Sepe,&nbsp;Melanie Claps,&nbsp;Luca Isella,&nbsp;Elena Verzoni,&nbsp;Giuseppe Procopio","doi":"10.1177/03008916221141483","DOIUrl":"https://doi.org/10.1177/03008916221141483","url":null,"abstract":"<p><strong>Background: </strong>The BONSAI phase II trial recently demonstrated the activity of cabozantinib in metastatic collecting duct patients. The outcomes of patients in this setting treated with immunotherapy as second-line is unknown. The aim of the present report was to describe outcomes of patients enrolled in the BONSAI trial that received nivolumab as second-line treatment.</p><p><strong>Material and methods: </strong>We describe the oncological outcomes in terms of overall response rate, progression-free survival, overall survival and safety. We excluded patients that did not receive any second-line treatment or were treated with agents other than nivolumab.</p><p><strong>Results: </strong>We identified five patients of whom one was excluded due to lack of data. Three patients obtained clinical benefit (one partial response, two stable disease); the second-line progression-free survival (nivolumab) ranged from 2.8 to 19.9 months to and second-line overall survival ranged from 5.1 to 26.5 months. No new safety signals were observed.</p><p><strong>Conclusions: </strong>Nivolumab may be considered as second-line therapy option after cabozantinib failure in selected metastatic collecting duct carcinoma patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"418-423"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/51/10.1177_03008916221141483.PMC10363925.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9921167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Lung metastasectomy for osteosarcoma in children, adolescents, and young adults: proof of permanent cure\".","authors":"","doi":"10.1177/03008916231186888","DOIUrl":"10.1177/03008916231186888","url":null,"abstract":"1Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy 2Chemotherapy Unit, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), IRCCS Istituto Ortopedico Rizzoli, Bologna University, Bologna, Italy 3Methodological Research Unit, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy 4Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy 5Italian Sarcoma Group (ISG), Italy","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 4","pages":"430"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552331/pdf/10.1177_03008916231186888.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10212022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}